Revance Therapeutics Inc. (RVNC) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Revance Therapeutics Inc. (RVNC)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.29

0.00 (0.00%)

At close: Jan 14, 2025, 3:59 PM

3.29

0.00%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	3.28
Market Cap	343.44M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.34
PE Ratio (ttm)	-0.99
Forward PE	n/a
Analyst	Hold

Ask	3.42
Volume	624,785
Avg. Volume (20D)	2,859,555
Open	3.27
Previous Close	3.29
Day's Range	3.27 - 3.31
52-Week Range	2.30 - 7.56
Beta	undefined

About RVNC

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to tre...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 6, 2014

Employees 597

Stock Exchange NASDAQ

Ticker Symbol RVNC

Website https://www.revance.com

Analyst Forecast

According to 9 analyst ratings, the average rating for RVNC stock is "Hold." The 12-month stock price forecast is $6, which is an increase of 82.37% from the latest price.

Buy 22.22%

Hold 77.78%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Revance Therapeutics Inc. is scheduled to release its earnings on Feb 26, 2025, during market hours.
Analysts project revenue of $75.60M, reflecting a 8.31% YoY growth and earnings per share of -0.31, making a -50.00% decrease YoY.

Why Price Moved

1 week ago · Source

+12.3%

Revance Therapeutics shares are trading higher aft... Unlock content with Pro Subscription

1 month ago · Source

-20.68%

Revance shares are trading lower after the company announced an amended and restated merger agreement with Crown Laboratories, under which Crown will commence a tender offer to acquire all outstanding shares of Revance's common stock for $3.10 per share in cash.

News

4 days ago · businesswire.com

RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK--(BUSINESS WIRE)---- $RVNC #RVNC--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed aga...

1 week ago · businesswire.com

RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

1 week ago · businesswire.com

Law Offices of Frank R. Cruz Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action.

1 week ago · businesswire.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors ...

1 week ago · businesswire.com

Law Offices of Howard G. Smith Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Revance Therapeutics, Inc. (“Revance” or the “C...

4 weeks ago · businesswire.com

REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Revance Therapeu...

1 month ago · businesswire.com

Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Revance (NASDAQ: RVNC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crown. Click here to learn how...

1 month ago · reuters.com

Revance agrees to lower-priced buyout offer by Crown Laboratories

Anti-wrinkle injection maker Revance Therapeutics has agreed to be bought for $3.10 per share by privately held Crown Laboratories, instead of $6.66 per share agreed previously, the two companies said...

1 month ago · businesswire.com

Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement

JOHNSON CITY & NASHVILLE, Tenn.--(BUSINESS WIRE)--Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement.

2 months ago · zacks.com

Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates

Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.74 per share a year ago.